{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemtuzumab+Ozogamicin&page=2",
    "query": {
      "intervention": "Gemtuzumab Ozogamicin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 71,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemtuzumab+Ozogamicin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemtuzumab+Ozogamicin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T02:08:03.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00895934",
      "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "gemtuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2009-05",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Bremerton, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Bremerton",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895934"
    },
    {
      "nct_id": "NCT01019317",
      "title": "Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "AML",
        "MDS",
        "CML"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2009-11",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2016-03-15",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019317"
    },
    {
      "nct_id": "NCT06448013",
      "title": "A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2025-03-07",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06448013"
    },
    {
      "nct_id": "NCT00038831",
      "title": "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Mylotarg",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 47,
      "start_date": "2001-05",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038831"
    },
    {
      "nct_id": "NCT00089050",
      "title": "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "gemtuzumab ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-05",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2011-11-30",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089050"
    },
    {
      "nct_id": "NCT00049179",
      "title": "S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "gemtuzumab ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2003-04",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 151,
      "location_summary": "Berkeley, California • Burlingame, California • Greenbrae, California + 95 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049179"
    },
    {
      "nct_id": "NCT00161668",
      "title": "Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Mylotarg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 500,
      "start_date": "2001-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-03-15",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 59,
      "location_summary": "Tucson, Arizona • Berkely, California • Burbank, California + 49 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkely",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161668"
    },
    {
      "nct_id": "NCT03839446",
      "title": "Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "mitoxantrone + etoposide + gemtuzumab ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert Redner, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-02-28",
      "completion_date": "2024-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03839446"
    },
    {
      "nct_id": "NCT00968071",
      "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2008-02",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968071"
    },
    {
      "nct_id": "NCT00003131",
      "title": "CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "gemtuzumab ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "1997-02",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2012-08-22",
      "last_synced_at": "2026-10-07T02:08:03.667Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Duarte, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003131"
    }
  ]
}